Favrille Inc.
This article was originally published in Start Up
Executive Summary
Favrille Inc. believes that it has found a way to significantly curtail cycle time for vaccine production, putting it in position to implement a workable business model for patient-specific therapies for lymphoma and diseases of the immune system.